Recent Updates
Recently added Catalysts

PF-05180999

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: May 1, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLED
Total Trials1
Total Enrollment12
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01530529A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999PHASE1 COMPLETED 12 — — Jan 1, 2012Apr 1, 2012May 1, 20121 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Maximum Observed Plasma Concentration (Cmax)
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose of each Period
Time to Reach Maximum Observed Plasma Concentration (Tmax)
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose of each Period
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose of each Period
Plasma Decay Half-Life (t1/2)
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose of each Period
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose of each Period
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
PF-05180999 Immediate-ReleaseEXPERIMENTAL -
PF-05180999 Modified-Release 1EXPERIMENTAL -
PF-05180999 Modified-Release 2EXPERIMENTAL -
PF-05180999 Modified-Release 1 With FoodEXPERIMENTAL -
Interventions
NameTypeDescription
PF-05180999DRUGSingle dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male or female of non-childbearing potential Exclusion Criteria: * Evidence of clinically-significant medical illness, history of seizures, any condition possibly affecting drug absorption

Countries:United States
Unlock Eligibility Criteria